Motilal Oswal Securities expects the mixed gross sales of Nifty constituents for the September-December interval to fall 2 per cent YoY. The brokerage count on (PAT) for the Nifty corporations to rise in single digits at 7 per cent YoY. Antique Stock Broking expects Nifty revenue to rise 3.Eight per cent and gross sales 2 per cent.
Among the businesses analysts expect to report robust outcomes are cement makers Shree Cement and UltraTech Cement. While Shree Cement is projected to report 105.Three per cent revenue progress to Rs 636.30 crore from Rs 310 crore, UltraTech Cement is predicted to report 72.Three per cent rise in revenue at Rs 1,390.40 crore in opposition to Rs 806.90 crore reported for the year-ago interval, Motilal Oswal Securities mentioned.
Brokerage Nirmal Bang expects revenue for UltraTech Cement to rise 58 per cent YoY to Rs 1,126 crore. It has projected Shree Cement to report 67.5 per cent revenue rising at Rs 519.Three crore.
A drop in depreciation and curiosity value and a soar in different revenue are anticipated to help Shree Cement’s numbers. Cement volumes are estimated to rise 14 per cent YoY. In case of UltraTech Cement, the corporate had supplied for a one-time expense of Rs 133.23 crore within the year-ago quarter as a part of different bills in opposition to varied disputed liabilities. No such expense this time, a fall in curiosity outgo and a 12 per cent rise in gross sales are anticipated to assist Ultratech’s December quarter numbers.
Motilal expects Cipla to report 83.60 per cent rise in revenue at Rs 644.60 crore and Sun Pharma to report 65.7 per cent revenue progress at Rs 1,378.50 crore. Edelweiss pegged YoY progress for Cipla at 54.1 per cent to Rs 595.70 crore and that for Sun Pharma at 50.Three per cent to Rs 1,268 crore.
“Revenue ($ 147 million) is expected to increase 4 per cent QoQ, driven by market share gain in gProventil. Moreover, Atripla and Truvada supplies to Teva would keep API strong (up 45 per cent YoY). We estimate Ebitda margin to improve 415 bps YoY to 21 per cent driven by cost savings,” Edelweiss mentioned.
For Sun Pharma, revenues are seen rising 7 per cent to Rs 8,625 crore. The firm could report a drop in curiosity outgo and rise in internet different revenue, analysts mentioned.
Motilal Oswal expects Hindalco’s revenue to rise 64.1 per cent to Rs 1,435.30 crore. It has projected JSW Steel to report multi-fold soar in revenue at Rs 2,245.10 crore. Edelweiss expects Hindalco’s revenue to develop 80 per cent to Rs 1918 crore and that of JSW to leap multi-fold to Rs 2,729.20 crore.
In the case of JSW Steel, the year-ago quarter was fairly dangerous, as the corporate reported an 88 per cent drop in revenue. In the case of Hindalco, the rise in revenue could be aided by improved LME aluminum costs.
Emkay Global expects IOC to clock a 126 per cent YoY progress in revenue at Rs 5,294.60 crore on a 13.9 per cent drop in gross sales at Rs 1,07,282 crore. The firm is prone to make foreign exchange good points as a result of weak greenback. Motilal expects 61.Eight per cent revenue progress from the OMC at Rs 3,783.80 crore. IOC, Motilal mentioned, can also be prone to profit from multi-year excessive petrochemicals margins throughout the quarter.
Inventory good points are seemingly at $2 a barrel, with gross advertising and marketing margins at Rs 5.Three per litre, it mentioned.